Metal-Based Drugs

Metal-Based Drugs / 1999 / Article

Open Access

Volume 6 |Article ID 935231 | https://doi.org/10.1155/MBD.1999.291

Simon P. Fricker, "A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes", Metal-Based Drugs, vol. 6, Article ID 935231, 10 pages, 1999. https://doi.org/10.1155/MBD.1999.291

A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes

Received28 Oct 1998
Accepted07 Mar 1999

Abstract

The use of a screening strategy based on human tumor cell lines, which are also tumorigenic in immune-deprived mice, is described. Activity against the human tumor cells in vitro and in vivo, is complemented with studies on the mechanism of action. This aporoach is demonstrated using 2-[(dimethylamino)-methyl]phenyl (damp) gold(III) compounds of the type [Au X2(damp)], where X = chloride, thiocyanate, acetate, or the bidentate ligands oxalate and malonate. All compounds were shown to be selectively active against a human bladder tumor cell line (HT1376) in vitro, and active in an in vitro panel of ovarian tumor cell lines. The acetato complex was shown to be active in experimental animal models of both the HT1376 bladder tumor, and the CH1 ovarian tumor. Although the [AuX2(damp)] compounds share structural features in common with cisplatin, and exhibit interesting in vivo activity against human tumor cells, the data indicate that they have a very different biochemical mechanism from platinum-based drugs and represent a potentially new class of metal-based antitumor agents.

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views74
Downloads7
Citations